Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Netherton Syndrome, Atopic Dermatitis, and Rare Skin Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KLK5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLK5 Recombinant Protein (Mature & Zymogen Forms) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed. |
View KLK5 Products |
| Mutant Control | KLK5 S195A Mutant Protein Catalytic serine-to-alanine mutant for selectivity counter-screens. Sequence Verified. |
View KLK5 Products |
| Gene Delivery | KLK5 Premade ORF / Lentivirus Full-length ORF for stable secreted expression in keratinocyte lines. |
View KLK5 Products |
| Benchmark Ab | Anti-KLK5 Recombinant Antibody Sequence Verified, Chimeric Rabbit Fc. Research-grade neutralizing control. |
View KLK5 Products |
| Validator | KLK5 siRNA Set For knockdown verification and specificity checks. |
View KLK5 Products |
| Related Target A | KLK7 Synergistic skin protease; co-dysregulated in Netherton syndrome. |
View KLK7 Products |
| Related Target B | SPINK5 (LEKTI) Endogenous inhibitor of KLK5; mutated in Netherton syndrome. |
View SPINK5 Products |
| Related Target C | KLK14 Subfamily member with overlapping substrate specificity; critical for selectivity profiling. |
View KLK14 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily selectivity (KLK5 vs KLK7 vs KLK14) | Homolog panel proteins strictly Sequence Verified; Human orthologs with >95% purity. Mass Spec verified identity. |
| Zymogen handling & mature enzyme conversion | Mature & Zymogen KLK5 available; HEK293 expressed for native folding, disulfide bond formation, and proper conformational epitopes. |
| Cross-species evaluation (mouse/cyno) | Human, Mouse, and Cynomolgus KLK5 recombinant proteins available with Endotoxin <1 EU/µg. |
| Lack of specificity controls | KLK5 S195A catalytic mutant included for counter-screening; KLK5 siRNA for target validation. |
| Enzymatic activity preservation | All KLK5 proteins expressed in HEK293 (native glycosylation) maintaining enzymatic activity. |
Live KLK5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLK5 therapeutics is intensifying. Major players are shifting focus from broad immunosuppressants and non-selective serine protease inhibitors to highly selective monoclonal antibodies and targeted biologics. In Netherton syndrome, hyperactive KLK5 due to SPINK5 mutation drives barrier dysfunction; recent advances include BridgeBio's BBP-361 entering Phase I/II trials. The next wave of R&D is expected to focus on dual kallikrein blockade (KLK5/KLK7), topical formulations to limit systemic exposure, and allosteric inhibitors that avoid active-site cross-reactivity. For competitive positioning, the key challenge remains achieving subfamily selectivity without disrupting global homeostatic networks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Early-stage biotech & dermatology-focused pharma | Netherton Syndrome, Atopic Dermatitis | Enzymatic Selectivity Assay (Need mature WT vs S195A mutant KLK5) |
| Monoclonal Antibody | Rare disease biotech portfolios | Netherton Syndrome, Rosacea, Severe Congenital Ichthyosis | Binding & Neutralization Assay (Need high-purity KLK5 antigen) |
| Topical Biologic / Peptide | Dermatology specialty firms | Psoriasis, Chronic Eczema | Cell-Based Secretion Assay (Need KLK5 Lentivirus for keratinocyte lines) |
| Gene Therapy | Rare Disease Focused | Genetic Skin Disorders | Expression Validation (Need Lentivirus/Stable Lines) |